araag2/HINT huggingface dataset:
Clinical trial NCT00624858 (phase 2, status: completed)
Conditions: depression
ICD codes: F32.A, F53.0, P91.4, Z13.31, Z13.32
Drugs: naltrexone sr 32 mg/ bupropion sr 360 mg daily
SMILES: OC1=CC=C2C[C@H]3N(CC=C)CC[C@@]45[C@@H](OC1=C24)C(=O)CC[C@@]35O
Eligibility criteria:

        Inclusion Criteria:

          -  Female and male subjects must be 18 to 65 years of age;

          -  Have body mass index (BMI) greater or equal to 27 and less than or to equal 43kg/m2;

          -  Meet criteria for major depression

          -  Women of child-bearing potential, must be non-lactating and agree to use effective
             contraception throughout the study period and 30 days after discontinuation of study
             drug;

          -  Able to comply with all required study procedures and schedule;

          -  Able to speak and read English;

          -  Willing and able to give written informed consent

        Exclusion Criteria:

          -  Obesity of known endocrine origin

          -  Serious medical condition

          -  History of drug or alcohol abuse or dependence

          -  Use of excluded concomitant medications

          -  History of surgical or device (e.g. gastric banding) intervention for obesity;

          -  History or predisposition to seizures

          -  Pregnant or breast-feeding women or planning to become pregnant during the study
             period or within 30 days of discontinuing study drug;

          -  Planned surgical procedure that can impact the conduct of the study;

          -  Use of investigational drug, device or procedure within 30 days prior to Screening;

          -  Participation in any previous clinical trial conducted by Orexigen Therapeutics;

          -  Any condition which in the opinion of the investigator makes the subject unsuitable
             for inclusion in the study.
Clinical trial NCT00427609 (phase 2, status: terminated)
Conditions: psoriasis
ICD codes: L40.0, L40.4, L40.8, L40.9, L40.1, L40.50
Drugs: bicillin l-a
SMILES: [H][C@]12SC(C)(C)[C@@H](N1C(=O)[C@H]2NC(=O)CC1=CC=CC=C1)C(O)=O
Reason stopped: 
    not enough enrollees to obtain a valid conclusion
  
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female between 18 and 50 years of age (with onset before age 40)

          -  Presence of chronic plaque type psoriasis unresponsive to treatment with topical
             preparations and extensive enough to consider appropriateness of systemic therapy

          -  Guttate forms of psoriasis

          -  Non-responsive to treatment or worsening of the pre-existing psoriasis

          -  With the exception of their skin disease , in good general state of health based on a
             complete medical history, blood test and urine analysis.

          -  Females must have negative urine pregnancy test and willing to take additional
             measures to keep from becoming pregnant during the course of the study

          -  No systemic prescription medication to control psoriasis within past 30 days

          -  Free of any topical antipsoriatic preparation for the duration of the study with the
             exception of emollients and moisturizers

        Exclusion Criteria:

          -  Pustular forms of psoriasis, either localized or generalized

          -  Generalized Erythrodermic psoriasis

          -  Only palmoplantar psoriasis

          -  Only scalp psoriasis

          -  Only nail psoriasis

          -  Only inverse psoriasis

          -  Diabetes or impaired glucose tolerance

          -  History of recurrent yeast infections

          -  History of hypersensitivity to Penicillin

          -  History of severe adverse drug reactions

          -  Pregnancy

          -  Lactation

          -  HIV/AIDS

          -  History of renal disease

          -  History of liver disease

          -  History or presence of alcohol and/or drug dependence or abuse

          -  History of significant psychiatric illness

          -  History of allergy, asthma, allergic rhinitis, or urticaria subjects in other research
             trials, at least 30 days prior to the beginning of this study
Clinical trial NCT00232726 (phase 2, status: completed)
Conditions: malignant melanoma, neoplasm metastasis
ICD codes: C43.0, C43.31, C43.51, C43.9, C43.4, C43.52, C43.10, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: cp-4055 (elacyt)
SMILES: [H]\C(CCCCCCCC)=C(\[H])CCCCCCCC(=O)OC[C@@]1([H])O[C@@]([H])(N2C=CC(=N)N=C2O)[C@@]([H])(O)[C@]1([H])O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients with histologically or cytologically confirmed stage IV or unresectable stage
             III non-ocular malignant melanoma who have not undergone prior chemotherapy for the
             treatment of melanoma (chemotherapy-naïve)

          -  Measurable disease according to Response Criteria in Solid Tumours (RECIST)

          -  Performance Status 0 - 2 according to ECOG (Eastern Cooperative Oncology Group)
             Performance Status

          -  Age 18 years or more

          -  Life expectancy > 3 months

          -  Signed informed consent

          -  Adequate haematological and biological functions:

               -  Bone marrow function:

                    1. Neutrophils ≥ 1.5 x 10^9/L

                    2. Platelets ≥ 100 x 10^9/L

                    3. Hemoglobin (Hb) ≥ 10 g/dL

               -  Hepatic function:

                    1. AST/ALT ≤ 2.5 times institutional upper limit of normal (ULN). If liver
                       metastases, ≤ 5 times institutional ULN.

                    2. Serum bilirubin and alkaline phosphatase ≤ 1.5 times institutional ULN

               -  Renal function:

                    -  Creatinine ≤ 1.5 times institutional ULN

        Exclusion Criteria:

          -  Known brain metastases

          -  Diagnosis of ocular malignant melanoma

          -  Radiotherapy to more than 30% of bone marrow

          -  Participation in another therapeutic clinical study within 30 days of enrolment or
             during this clinical study

          -  Prior immunotherapy and/or chemotherapy for the treatment of melanoma

          -  Requirement of concomitant treatment with a non-permitted medication:

               -  Alternative drugs

               -  High doses of vitamins

          -  History of allergic reactions to Ara-C or egg

          -  Presence of any serious concomitant systemic disorders incompatible with the clinical
             study (e.g. uncontrolled intercurrent illness including ongoing or active infection)

          -  Presence of any significant central nervous system or psychiatric disorder(s) that
             would hamper the patient's compliance

          -  Pregnancy, breastfeeding, or absence of adequate contraception for both male and
             female fertile patients

          -  Known positive status for HIV and/or hepatitis B or C

          -  Drug and/or alcohol abuse

          -  Any reason why, in the Investigator's opinion, the patient should not participate
Clinical trial NCT00214266 (phase 2, status: completed)
Conditions: renal transplantation
ICD codes: N25.0, Q61.4, N23, N26.9, P96.0, Q60.0, Q60.1
Drugs: campath 1h®, rituximab, mycophenolate mofetil
SMILES: COC1=C(C\C=C(/C)CCC(O)=O)C(O)=C2C(=O)OCC2=C1C
Eligibility criteria:

        Inclusion Criteria:

          -  renal transplant recipients

        Exclusion Criteria:

          -  Recipients of HLA-identical living-donor renal transplants;

          -  multi-organ transplant;

          -  known hypersensitivity to Campath-1H, Rituximab, CellCept, or prednisone;
Clinical trial NCT01464827 (phase 2, status: completed)
Conditions: chronic hepatitis c, hepatitis c (hcv), hepatitis c genotype 1
ICD codes: B18.2, B18.0, B18.1, B18.8, B18.9, K71.3, K71.4, B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2, B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: abt-450, abt-333, abt-267, ribavirin, ritonavir
SMILES: [H][C@@]12C[C@]1(NC(=O)[C@]1([H])C[C@H](CN1C(=O)[C@H](CCCCC\C=C/2)NC(=O)C1=CN=C(C)C=N1)OC1=NC2=C(C=CC=C2)C2=C1C=CC=C2)C(=O)NS(=O)(=O)C1CC1, COC1=C(C=C(C=C1C1=CC2=CC=C(NS(C)(=O)=O)C=C2C=C1)N1C=CC(=O)NC1=O)C(C)(C)C, COC(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1C(=O)NC1=CC=C(C=C1)[C@@H]1CC[C@H](N1C1=CC=C(C=C1)C(C)(C)C)C1=CC=C(NC(=O)[C@@H]2CCCN2C(=O)[C@@H](NC(=O)OC)C(C)C)C=C1, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O, CC(C)[C@H](N1CCCNC1=O)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)COC1=C(C)C=CC=C1C)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females 18-70 years old, inclusive

          -  Females must be post-menopausal for more than 2 years or surgically sterile or
             practicing specific forms of birth control

          -  Chronic hepatitis C virus (HCV), genotype 1 infection

          -  Treatment-naive OR null-responders to previous treatment with pegylated interferon
             (pegIFN) and ribavirin (at least 12 weeks of treatment and failure to achieve a 2
             log10 HCV RNA decrease at Week 12)

          -  No evidence of liver cirrhosis

        Exclusion Criteria:

          -  Significant liver disease with any cause other than HCV as the primary cause

          -  Positive hepatitis B surface antigen and anti-human immunodeficiency virus antibody

          -  Positive screen for drugs and alcohol

          -  Significant sensitivity to any drug

          -  Use of contraindicated or prohibited medications within 1 month of dosing

          -  Abnormal laboratory tests
Clinical trial NCT00527033 (phase 2, status: completed)
Conditions: urinary bladder, overactive
ICD codes: N32.81
Drugs: ym178, placebo
SMILES: NC1=NC(CC(=O)NC2=CC=C(CCNC[C@H](O)C3=CC=CC=C3)C=C2)=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients over 20 years suffering from overactive bladder

        Exclusion Criteria:

          -  Pregnant and breastfeeding women

          -  Any clinically significant abnormal conditions which in the opinion of the
             investigator makes the patient unsuitable for the study
Clinical trial NCT00551759 (phase 2, status: terminated)
Conditions: esophageal cancer
ICD codes: K22.2, K22.81, Q39.4, P78.83, I85.00, I85.01, I85.10
Drugs: 5-fluorouracil, oxaliplatin, cetuximab, docetaxel
SMILES: FC1=CNC(=O)NC1=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12SCC(COC(C)=O)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    the study used a two-stage design. after stage one, the study was terminated due to excess
    toxicity.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Newly diagnosed adenocarcinoma of the esophagus (> 20 cm below the incisors) or
             gastroesophageal (GE) junction, untreated with chemotherapy, radiation therapy, and
             surgery. Endoscopy with biopsy and dilation was permitted.

          -  Tumor stage T2N0M0, T3N0M0, T1-3N+M0, or T1-3N0-1M1A as determined by imaging studies
             performed no greater than 4 weeks prior to registration, and biopsy, where
             appropriate. Celiac nodal metastasis (M1A disease) was permitted if other eligibility
             criteria were met. Data from endoscopic ultrasound and endoscopy were required for
             staging. The following imaging was required: CT scan with IV contrast and PET or
             PET+CT. If the PET/CT incorporates CT with IV contrast, then a separate CT is not
             required. If laparoscopy or other relevant procedures were performed, the data were to
             be incorporated into stage assignment. Any lesion suspicious for metastasis had to
             have been biopsied to prove eligibility.

          -  Tumor extension into cardia, if present, must have been no more than 2 cm.

          -  Tumors must have been considered surgically resectable (T1-3, not T4).

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1

          -  Granulocytes > 1,000/ mm³

          -  Platelets > 100,000 μL

          -  Creatinine normal or creatinine clearance > 60 mL/min

          -  Total serum bilirubin < 1.5 mg/dL

          -  Fertile patients must use effective contraception

          -  History of a curatively treated malignancy from which the patient has been
             disease-free for ≥ 2 years and has a survival prognosis of > 5 years

        Exclusion Criteria:

          -  Pregnant or breast-feeding.

          -  Prior severe infusion reaction to a monoclonal antibody

          -  prior therapy specifically and directly targeting the epidermal growth factor receptor
             (EGFR) pathway

          -  Hypertension

          -  Uncontrolled diabetes

          -  Intercurrent illness that would likely interfere with protocol therapy or prevent
             surgical resection

          -  Any of the following within the past 6 months:

               -  New York Heart Association class III-IV congestive heart failure

               -  Cerebrovascular accident or transient ischemic attack

               -  Unstable angina or myocardial infarction
Clinical trial NCT00487656 (phase 2, status: completed)
Conditions: sepsis, disseminated intravascular coagulation
ICD codes: A02.1, A22.7, A26.7, A32.7, A42.7, A54.86, B37.7
Drugs: art-123, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Infection or suspected infection resulting in sepsis and DIC

        Exclusion Criteria:

          -  Unable to provide informed consent, or lack of consent from an acceptable surrogate

          -  Subjects < 18 years of age

          -  Known conditions that could confound the diagnosis of DIC due to sepsis

          -  Known conditions that increase the risk of bleeding

          -  Known medical condition associated with a hypercoagulable state

          -  Known or suspected severe liver disease

          -  History of solid organ (excluding uncomplicated kidney), bone marrow or stem cell
             transplantation

          -  Renal failure
Clinical trial NCT00159445 (phase 2, status: completed)
Conditions: colorectal cancer, colon cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C18.2, C18.4, C18.6, C18.7, C18.9, D12.2, D12.3
Drugs: gemcitabine, capecitabine
SMILES: NC1=NC(=O)N(C=C1)[C@@H]1O[C@H](CO)[C@@H](O)C1(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed metastatic adenocarcinoma of the colon or rectum, with
             measurable disease. The primary histologic diagnosis is sufficient if there is clear
             evidence by imaging and/or markers of metastatic disease sites.

          -  Patients must have failed CPT-11 and oxaliplatin based therapies.

          -  Patients must have received at least two prior chemotherapy regimens for advanced
             disease (completed > 4 weeks prior to enrollment).

          -  Tumor must be accessible for biopsy or paraffin embedded tissue must be available for
             review.

          -  SWOG performance status 0-2.

          -  AGC >1000, platelets >100,000.

          -  Total bilirubin < 3 x upper limit of normal. Transaminase (AST and/or ALT) < 2 x upper
             limit of normal or < 5 x upper limit of normal in patients with liver metastasis.

          -  Patients must have a measured or calculated creatinine clearance greater than 35
             mL/min obtained within 28 days prior to registration.

          -  Age greater than or equal to 18 years

          -  Patients should have hemoglobin > 9 g/dL; patients may be transfused to achieve this
             level of hemoglobin.

          -  Except for cancer-related abnormalities, patients should not have unstable or
             pre-existing major medical conditions.

        Exclusion Criteria:

          -  History of a malignancy other than colon or rectal cancer, except for adequately
             treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other
             cancer for which the patient has been disease-free for five years.

          -  Patients with brain metastasis.

          -  History of recent (within one year) myocardial infarction or evidence of congestive
             heart failure.

          -  Patients that have psychological, familial, sociological, or geographical conditions
             that do not permit medical follow-up and compliance with the study protocol.

          -  Patients should not have any immediate life-threatening complications of their
             malignancies.
Clinical trial NCT00500292 (phase 2, status: completed)
Conditions: colorectal, cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: vandetanib, folfox regimen=oxaliplatin, fluorouracil, & folinic acid
SMILES: [H]\C(=C(\[H])C1=CC=C(OC)C=C1)C(=O)OCC(CC)CCCC
Eligibility criteria:

        Inclusion Criteria:

          -  Progression on or following treatment for metastatic colorectal cancer

          -  Have failed therapy with an irinotecan and fluoropyrimidine containing regimen

          -  Have World Health Organisation (WHO) performance status 0-2 and life expectancy >12
             weeks

        Exclusion Criteria:

          -  Previous treatment with small molecule tyrosine kinase inhibitors of VEGFR or EGFR
             Prior monoclonal antibodies are permitted, (eg, cetuximab, bevacizumab)

          -  Previous adjuvant therapy with irinotecan within 12 months of randomisation

          -  More than one prior course of chemotherapy for treatment of metastatic colorectal
             cancer
Clinical trial NCT01405911 (phase 2, status: completed)
Conditions: glucose intolerance
ICD codes: E73.8, E73.9, E74.12, K90.49
Drugs: placebo for sitagliptin 25 mg, placebo for sitagliptin 50 mg, sitagliptin 25 mg, sitagliptin 50 mg
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F
Eligibility criteria:

        Inclusion Criteria:

          -  Impaired glucose tolerance

          -  On diet/exercise therapy

          -  Unlikely to conceive

          -  Meets all of the following glycemic parameters: Hemoglobin A1c (Japan Diabetes Society
             value) <6.1%, Fasting Plasma Glucose <126 mg/dL, and 2-hr plasma glucose level in 75g
             oral glucose tolerance test ≥140 mg/dL and <200 mg/dL

        Exclusion Criteria:

          -  History of diabetes mellitus

          -  Disease or condition of clear or likely glucose tolerance disorder

          -  Previously treated with a drug to prevent diabetes and/or any antihyperglycemic drug
Clinical trial NCT01387958 (phase 2, status: terminated)
Conditions: hepatitis c
ICD codes: B18.2, B17.10, B17.11, B19.20, B19.21, B15.0, B15.9
Drugs: lcq908, placebo
SMILES: OC(=O)C[C@H]1CC[C@@H](CC1)C1=CC=C(C=C1)C1=NC=C(NC2=CN=C(C=C2)C(F)(F)F)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    terminated early due to futility
  
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent.

          -  Male and female subjects 18 to 65 years of age with hepatitis C infections (genotypes
             1, 2 or 3).

          -  No prior therapy or inadequate response to therapy for hepatitis C.

          -  Weight at least 50 kg and body mass index (BMI) within 18 - 35 kg/m2.

        Exclusion Criteria:

          -  Use of other investigational drugs within at least 30 days of enrollment

          -  Women of child-bearing potential.

        Other protocol-defined inclusion/exclusion criteria apply
Clinical trial NCT01035671 (phase 2, status: completed)
Conditions: friedreich's ataxia
ICD codes: G11.11
Drugs: alpha-tocopherolquinone (a0001), alpha-tocopherolquinone (a0001), placebo
SMILES: CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O, CC(C)CCC[C@@H](C)CCC[C@@H](C)CCC[C@@](C)(O)CCC1=C(C)C(=O)C(C)=C(C)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Individuals with genetically confirmed Friedreich's Ataxia (GAA or point mutation)

          -  Impaired Glucose Tolerance, measured by Oral GTT

        Exclusion Criteria:

          -  Overt Diabetes Mellitus

          -  Presence of clinically significant cardiovascular disease
Clinical trial NCT01782508 (phase 2, status: unknown status)
Conditions: melanoma
ICD codes: C43.0, C43.31, D03.9, C43.51, C43.9, D03.0, C43.4
Drugs: imatinib, interferon
SMILES: CC1=NC(NC2=NC=C(S2)C(=O)NC2=C(C)C=CC=C2Cl)=CC(=N1)N1CCN(CCO)CC1, CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Melanoma patients whose primary tumor and regional lymphonodes (if have)have been
             resected

          -  Histologically documented AJCC stage IIB to IIIC

          -  C-kit mutation documented from either primary or metastatic lymphnode site

          -  ECOG performance status 0 or 1

          -  Age 18 years or older

          -  Creatinine < 1.5 x ULN

          -  ANC > 1500 ul

          -  Platelets > 100,000 ul

          -  Total bilirubin, AST, and ALT < 2 x ULN

          -  Amylase and lipase < 1.5 x ULN

          -  no prior chemotherapy or investigational drug

        Exclusion Criteria:

          -  Severe and/or uncontrolled medical disease

          -  Pregnant or nursing mothers

          -  Any other significant medical, surgical, or psychiatric condition that may interfere
             with compliance

          -  Patient is < 5 years free of another primary malignancy except: basal cell skin cancer
             or a cervical carcinoma in situ

          -  Concurrent treatment with Warfarin

          -  Prior treatment with c-kit inhibitor

          -  Patient with Grade III/IV cardiac problems as defined by NYHA criteria

          -  No H2 blockers or proton pump inhibitors

          -  Known chronic liver disease

          -  Known diagnosis of HIV infection

          -  Major surgery within 2 weeks prior to study entry

          -  Patient has received any other investigational agent within 28 days of first study
             drug dosing

          -  Chemotherapy within 4 weeks prior to study entry